SLC5A2 and diabetes mellitus: Providers had significant improvement in their comfort with oral adjuvant therapy in the treatment of insulin-requiring diabetes including the use of GLP1 agonists and SGLT2 inhibitors (pre vs post: 60.8% vs. 78.4%, p=0.007) and endorsed an ability to identify contraindications in diabetes medications (pre vs post: 52.0% vs. 88.0%, p<0.0001).